New weight loss drugs, such as Novo Nordisk’s Ozempic and Wegovy (semaglutide) and Eli Lilly’s Mounjaro (tirzepatide), could be transformative for people who struggle with obesity and obesity-related medical conditions, but there are major questions to consider related to insurance coverage, the cost of the drugs, and who has access. Importantly, by law, the drugs<span class="readmore-ellipsis">…</span><a href="https://www.kff.org/medicare/event/august-4-web-event-new-weight-loss-drugs-raise-issues-of-coverage-cost-access-and-equity/" class="see-more light-beige no-float inline-readmore">More</a></p>
Pharmacy benefit managers (PBMs) are increasingly scrutinized intermediaries in the U.S. health care system, negotiating discounts on prescription medications for health insurers and employers while collecting rebates from drugmakers. Even as PBMs have taken on a larger role in drug coverage and pricing in recent decades, including through mergers with insurers, the business arrangements that<span class="readmore-ellipsis">…</span><a href="https://www.kff.org/health-costs/event/june-14-web-event-probing-the-power-and-practices-of-pharmacy-benefit-managers/" class="see-more light-beige no-float inline-readmore">More</a></p>
The idea of imposing work requirements in Medicaid is making a comeback in Congress and at the state level. Some House Republicans are pushing to include such a measure in any deal to raise the debt ceiling. The policy resonates with a larger message of personal responsibility, and advocates suggest that work requirements could help<span class="readmore-ellipsis">…</span><a href="https://www.kff.org/medicaid/event/april-25-medicaid-work-requirements/" class="see-more light-beige no-float inline-readmore">More</a></p>